{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:51:03Z","timestamp":1770907863011,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background: Carnitine deficiency has been implicated as a potential pathway for cancer-related fatigue that could be treated with carnitine supplementation. The aim of this systematic literature review and meta-analysis was to evaluate the literature regarding the use of supplemental carnitine as a treatment for cancer-related fatigue. Methods: Using the PRISMA guidelines, an electronic search of the Cochrane Library, MEDLINE, Embase, CINAHL and reference lists was conducted. Data were extracted and independently assessed for quality using the Academy of Nutrition and Dietetics evidence analysis by two reviewers. In studies with positive quality ratings, a meta-analysis was performed using the random-effects model on Carnitine and cancer-related fatigue. Results: Twelve studies were included for review with eight reporting improvement in measures of fatigue, while four reported no benefit. However, many studies were non-randomized, open-label and\/or used inappropriate dose or comparators. Meta-analysis was performed in three studies with sufficient data. Carnitine did not significantly reduce cancer-related fatigue with a standardized mean difference (SMD) of 0.06 points ((95% CI \u22120.09, 0.21); p = 0.45). Conclusion: Results from studies with lower risk of bias do not support the use of carnitine supplementation for cancer-related fatigue.<\/jats:p>","DOI":"10.3390\/nu9111224","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T11:46:01Z","timestamp":1510055161000},"page":"1224","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy and Effectiveness of Carnitine Supplementation for Cancer-Related Fatigue: A Systematic Literature Review and Meta-Analysis"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-8230","authenticated-orcid":false,"given":"Wolfgang","family":"Marx","sequence":"first","affiliation":[{"name":"School of Allied Health, College of Science, Health and Engineering, La Trobe University, Melbourne, VIC 3086, Australia"},{"name":"Faculty of Health Sciences & Medicine, Bond University, Gold Coast, QLD 4226, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laisa","family":"Teleni","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences & Medicine, Bond University, Gold Coast, QLD 4226, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Opie","sequence":"additional","affiliation":[{"name":"School of Allied Health, College of Science, Health and Engineering, La Trobe University, Melbourne, VIC 3086, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimon","family":"Kelly","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences & Medicine, Bond University, Gold Coast, QLD 4226, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8953-5068","authenticated-orcid":false,"given":"Skye","family":"Marshall","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences & Medicine, Bond University, Gold Coast, QLD 4226, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1397-4149","authenticated-orcid":false,"given":"Catherine","family":"Itsiopoulos","sequence":"additional","affiliation":[{"name":"School of Allied Health, College of Science, Health and Engineering, La Trobe University, Melbourne, VIC 3086, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Isenring","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences & Medicine, Bond University, Gold Coast, QLD 4226, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lawrence, D.P., Kupelnick, B., Miller, K., Devine, D., and Lau, J. (2004). Evidence report on the occurrence, assessment and treatment of fatigue in cancer patients. J. Natl. Cancer Inst. Monogr.","DOI":"10.1093\/jncimonographs\/lgh027"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cncr.10630","article-title":"Changing patient perceptions of the side effects of cancer chemotherapy","volume":"95","author":"Carelle","year":"2002","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.1998.16.5.1689","article-title":"Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer","volume":"16","author":"Broeckel","year":"1998","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1023\/B:JOBM.0000047608.03692.0c","article-title":"Ecological momentary assessment of fatigue following breast cancer treatment","volume":"27","author":"Curran","year":"2004","journal-title":"J. Behav. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10549-006-9447-x","article-title":"Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients","volume":"105","author":"Groenvold","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/jnci\/djr485","article-title":"Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival","volume":"103","author":"Quinten","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.21671","article-title":"Fatigue in long-term breast carcinoma survivors: A longitudinal investigation","volume":"106","author":"Bower","year":"2006","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue mdash mechanisms, risk factors and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpedi.1987.04460060076039","article-title":"Plasma carnitine deficiency. Clinical observations in 51 pediatric patients","volume":"141","author":"Winter","year":"1987","journal-title":"Am. J. Dis. Child."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/MPH.0b013e3181b259a7","article-title":"Carnitine plasma levels and fatigue in children\/adolescents receiving cisplatin, ifosfamide, or doxorubicin","volume":"31","author":"Hockenberry","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3109\/00016489.2015.1030769","article-title":"Carnitine is associated with fatigue following chemoradiotherapy for head and neck cancer","volume":"135","author":"Endo","year":"2015","journal-title":"Acta Oto-Laryngol."},{"key":"ref_13","unstructured":"Marx, W., Teleni, L., Ferguson, M., Walpole, E., and Isenring, E. (2014). The Effect of Chemotherapy on Serum Carnitine Levels and Fatigue in Chemotherapy Na\u00efve Medical Oncology Patients: A Pilot Study. Carnitine, Chemotherapy and Fatigue. J. Nutr. Disord. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00280-006-0341-3","article-title":"Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment","volume":"60","author":"Mancinelli","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s002800050963","article-title":"Increased urinary losses of carnitine during ifosfamide chemotherapy","volume":"44","author":"Marthaler","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00394-013-0511-0","article-title":"Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: Evidence from experimental and clinical studies","volume":"52","author":"Ringseis","year":"2013","journal-title":"Eur. J. Nutr."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref_19","unstructured":"(2017, October 07). Review Manager (RevMan). Available online: http:\/\/community.cochrane.org\/tools\/review-production-tools\/revman-5."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Hershman, D.L., Unger, J.M., Crew, K.D., Minasian, L.M., Awad, D., Moinpour, C.M., Hansen, L., Lew, D.L., Greenlee, H., and Fehrenbacher, L. (2013). Randomized Double-Blind Placebo-Controlled Trial of Acetyl-l-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. J. Clin. Oncol.","DOI":"10.1200\/JCO.2012.44.8738"},{"key":"ref_21","unstructured":"Higgins, J.P.T., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1475-2891-11-52","article-title":"l-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)\u2014A randomized multicentre trial","volume":"11","author":"Kraft","year":"2012","journal-title":"Nutr. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jpainsymman.2008.03.021","article-title":"l-carnitine supplementation in patients with advanced cancer and carnitine deficiency: A double-blind, placebo-controlled study","volume":"37","author":"Cruciani","year":"2009","journal-title":"J. Pain Symptom Manag."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2011.40.2180","article-title":"l-carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"30","author":"Cruciani","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ygyno.2011.12.435","article-title":"A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynaecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life","volume":"124","author":"Maccio","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1634\/theoncologist.2009-0153","article-title":"Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia","volume":"15","author":"Mantovani","year":"2010","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jpainsymman.2006.09.001","article-title":"Safety, tolerability and symptom outcomes associated with l-carnitine supplementation in patients with cancer, fatigue and carnitine deficiency: A phase I\/II study","volume":"32","author":"Cruciani","year":"2006","journal-title":"J. Pain Symptom Manag."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nut.2005.06.003","article-title":"Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress and related quality of life in 12 advanced cancer patients undergoing anticancer therapy","volume":"22","author":"Gramignano","year":"2006","journal-title":"Nutrition"},{"key":"ref_29","first-page":"637","article-title":"Efficacy and safety of an amino acid jelly containing coenzyme Q10 and l-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: A multi-institutional, randomized, exploratory trial (JORTC-CAM01)","volume":"24","author":"Iwase","year":"2016","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib +\/\u2212 megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome","volume":"31","author":"Madeddu","year":"2012","journal-title":"Clin. Nutr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.bjc.6600413","article-title":"Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients","volume":"86","author":"Graziano","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00280-014-2550-5","article-title":"Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: A study from the Wisconsin Oncology Network","volume":"74","author":"Callander","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e20532","DOI":"10.1200\/jco.2009.27.15_suppl.e20532","article-title":"Phase III randomized, placebo-controlled trial of l-carnitine supplementation for fatigue in patients with cancer","volume":"27","author":"Cruciani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00555510","article-title":"Pharmacokinetics of bolus intravenous and oral doses of l-carnitine in healthy subjects","volume":"35","author":"Harper","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/0091270006292851","article-title":"Disposition and metabolite kinetics of oral l-carnitine in humans","volume":"46","author":"Bain","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s002280050504","article-title":"Increased urinary excretion of carnitine in patients treated with cisplatin","volume":"54","author":"Heuberger","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00204-014-1341-4","article-title":"The influence of chronic l-carnitine supplementation on the formation of preneoplastic and atherosclerotic lesions in the colon and aorta of male F344 rats","volume":"89","author":"Empl","year":"2015","journal-title":"Arch. Toxicol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/9\/11\/1224\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:48:32Z","timestamp":1760208512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/9\/11\/1224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"alternative-id":["nu9111224"],"URL":"https:\/\/doi.org\/10.3390\/nu9111224","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]}}}